File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Urotensin II: Its function in health and its role in disease

TitleUrotensin II: Its function in health and its role in disease
Authors
KeywordsHypertension
Urotensin II
Vasoactive peptides
Vasoconstriction
Issue Date2005
PublisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0920-3206
Citation
Cardiovascular Drugs And Therapy, 2005, v. 19 n. 1, p. 65-75 How to Cite?
AbstractUrotensin II (U-II) is the most potent vasoconstrictor known, even more potent than endothelin-1. It was first isolated from the fish spinal cord and has been recognized as a hormone in the neurosecretory system of teleost fish for over 30 years. After the identification of U-II in humans and the orphan human G-protein-coupled receptor 14 as the urotensin II receptor, UT, many studies have shown that U-II may play an important role in cardiovascular regulation. Human urotensin II (hU-II) is an 11 amino acid cyclic peptide, generated by proteolytic cleavage from a precursor prohormone. It is expressed in the central nervous system as well as other tissues, such as kidney, spleen, small intestine, thymus, prostate, pituitary, and adrenal gland and circulates in human plasma. The plasma U-II level is elevated in renal failure, congestive heart failure, diabetes mellitus, systemic hypertension and portal hypertension caused by liver cirrhosis. The effect of U-II on the vascular system is variable, depending on species, vascular bed and calibre of the vessel. The net effect on vascular tone is a balance between endothelium-independent vasoconstriction and endothelium-dependent vasodilatation. U-II is also a neuropeptide and may play a role in tumour development. The development of UT receptor antagonists may provide a useful research tool as well as a novel treatment for cardiorenal diseases. © 2005 Springer Science + Business Media, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/48633
ISSN
2015 Impact Factor: 3.189
2015 SCImago Journal Rankings: 1.114
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorOng, KLen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorCheung, BMYen_HK
dc.date.accessioned2008-05-22T04:19:34Z-
dc.date.available2008-05-22T04:19:34Z-
dc.date.issued2005en_HK
dc.identifier.citationCardiovascular Drugs And Therapy, 2005, v. 19 n. 1, p. 65-75en_HK
dc.identifier.issn0920-3206en_HK
dc.identifier.urihttp://hdl.handle.net/10722/48633-
dc.description.abstractUrotensin II (U-II) is the most potent vasoconstrictor known, even more potent than endothelin-1. It was first isolated from the fish spinal cord and has been recognized as a hormone in the neurosecretory system of teleost fish for over 30 years. After the identification of U-II in humans and the orphan human G-protein-coupled receptor 14 as the urotensin II receptor, UT, many studies have shown that U-II may play an important role in cardiovascular regulation. Human urotensin II (hU-II) is an 11 amino acid cyclic peptide, generated by proteolytic cleavage from a precursor prohormone. It is expressed in the central nervous system as well as other tissues, such as kidney, spleen, small intestine, thymus, prostate, pituitary, and adrenal gland and circulates in human plasma. The plasma U-II level is elevated in renal failure, congestive heart failure, diabetes mellitus, systemic hypertension and portal hypertension caused by liver cirrhosis. The effect of U-II on the vascular system is variable, depending on species, vascular bed and calibre of the vessel. The net effect on vascular tone is a balance between endothelium-independent vasoconstriction and endothelium-dependent vasodilatation. U-II is also a neuropeptide and may play a role in tumour development. The development of UT receptor antagonists may provide a useful research tool as well as a novel treatment for cardiorenal diseases. © 2005 Springer Science + Business Media, Inc.en_HK
dc.format.extent236462 bytes-
dc.format.extent99166 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.languageengen_HK
dc.publisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0920-3206en_HK
dc.relation.ispartofCardiovascular Drugs and Therapyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsThe original publication is available at www.springerlink.comen_HK
dc.subjectHypertensionen_HK
dc.subjectUrotensin IIen_HK
dc.subjectVasoactive peptidesen_HK
dc.subjectVasoconstrictionen_HK
dc.titleUrotensin II: Its function in health and its role in diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0920-3206&volume=19&issue=1&spage=65&epage=75&date=2005&atitle=Urotensin+II:+its+function+in+health+and+its+role+in+diseaseen_HK
dc.identifier.emailLam, KSL:ksllam@hku.hken_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturepostprinten_HK
dc.identifier.doi10.1007/s10557-005-6899-xen_HK
dc.identifier.pmid15883758-
dc.identifier.scopuseid_2-s2.0-20044372934en_HK
dc.identifier.hkuros98176-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-20044372934&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue1en_HK
dc.identifier.spage65en_HK
dc.identifier.epage75en_HK
dc.identifier.isiWOS:000229001300010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridOng, KL=8340854000en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.citeulike198811-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats